Diabetes and COVID19: a bidirectional relationship

Area of Science:

• Endocrinology
• Infectious Diseases
• Public Health

Background:

• The COVID-19 pandemic highlighted the impact of comorbidities like diabetes on disease outcomes.
• Hyperglycemia, regardless of cause, is linked to severe COVID-19, including respiratory distress, ICU admission, and mortality.
• COVID-19 infection can trigger new-onset diabetes and exacerbate glycemic control in individuals with pre-existing diabetes.

Purpose of the Study:

• To examine the intricate relationship between diabetes, hyperglycemia, and COVID-19 outcomes.
• To understand how COVID-19 affects glucose metabolism and diabetes management.
• To review the implications of public health measures on diabetes care during the pandemic.

Main Methods:

• Review of existing literature and clinical observations regarding diabetes and COVID-19.
• Analysis of the mechanisms linking SARS-CoV-2 infection to glycemic dysregulation.
• Assessment of treatment strategies for diabetic patients with COVID-19.

Main Results:

• Diabetes itself does not increase COVID-19 infection risk.
• Hyperglycemia is a significant predictor of severe COVID-19 and increased mortality.
• SARS-CoV-2 infection can lead to new-onset hyperglycemia/diabetes and worsen glycemic control through direct viral effects, inflammatory responses, and medication side effects.
• Pandemic-related restrictions can negatively impact diabetes self-management and access to care.
• Insulin therapy is recommended for severe COVID-19 cases in diabetic patients.

Conclusions:

• Hyperglycemia is a critical factor in COVID-19 severity and mortality.
• COVID-19 poses a dual threat to diabetic individuals by worsening glycemic control and potentially causing new-onset diabetes.
• Management strategies must adapt to the unique challenges faced by diabetic patients during the pandemic, with a preference for insulin in severe cases.